Evidence hub

Chronic Kidney Disease: cell-therapy evidence by therapy class

Across every stem-cell intervention, ClinicalTrials.gov holds 88 registered records for Chronic Kidney Disease — 9 recruiting, 10 at Phase 3 or 4, in 28 countries. Snapshot 2026-08-29.

Medical review statusMedically reviewedReviewed by: Stem Plus medical teamReviewed on: 2026-08-29Last evidence update: 2026-08-29Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

The condition, and why cells are proposed

Chronic kidney disease is progressive nephron loss with fibrosis and inflammation. Cell approaches aim to slow decline rather than regenerate nephrons, and the kidney's limited regenerative capacity makes restoration claims implausible. Registered work sits close to nephrology practice, which means endpoints are unusually well defined compared with softer indications.

Therapy classes side by side

Therapy classRegisteredRecruitingPhase 3/4Countries
MSC23516
HSCT352419
exosomes3103
PRP0000

Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.

Geography of the research

United States accounts for about 64% of country mentions among sampled studies; 28 countries host at least one site.

CountryStudies with a site there
United States54
Italy7
China6
Germany4
Spain3
South Korea3
Brazil2
India2

The largest registered studies

Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.

StudyPhaseStatusPlanned nLead sponsorStart
NCT03899298 — Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical ConditionsPhase 1Not Yet Recruiting5,000R3 Stem Cell2019-09-01
NCT02639936 — New Generation IGRA in Immunocompromised Individualsn/aCompleted2,663Tuberculosis Network European Trialsgroup2015-12
NCT00949052 — Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancern/aTerminated1,000Vanderbilt-Ingram Cancer Center2009-01
NCT00003883 — Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow TransplantationPhase 3Completed578Fred Hutchinson Cancer Center1998-10
NCT00957736 — Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplantn/aTerminated252Vanderbilt-Ingram Cancer Center2008-11
NCT01305200 — Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantPhase 3Completed226Children's Oncology Group2011-03

Most recently registered

StudyPhaseStatusPlanned nLead sponsorStart
NCT07592000 — Breakthrough - T1DM and Chronic Kidney Diseasen/aRecruitingn/aUniversity of Chicago2027-04-29
NCT07358195 — Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantationn/aNot Yet Recruitingn/aMassachusetts General Hospital2026-07
NCT07572890 — Adia Med of Winter Park LLC Chronic Kidney Disease Research Studyn/aRecruitingn/aAdia Med of Winter Park LLC2026-05-18
NCT07275788 — A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)n/aRecruitingn/aRegend Therapeutics2026-01-08
NCT07240987 — Mesenchymal Stem Cells for Chronic Kidney Diseasesn/aNot Yet Recruitingn/aThe First Affiliated Hospital of Air Force Medicial Universi2026-01-01

Reading this honestly

None of these numbers say the therapy works. They say how much organised research exists and how far along it is; effect sizes live in published results, not registry entries. For Chronic Kidney Disease specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.

Frequently asked

How many stem-cell trials exist for Chronic Kidney Disease?

88 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 9 were recruiting.

Which therapy class is furthest along for Chronic Kidney Disease?

Ranked by Phase 3/4 records: HSCT (4), MSC (1), exosomes (0), PRP (0).

Does a recruiting trial mean I can be treated?

No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads

Download the query data

Download CSV · Download JSON

Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.